Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2013 1
2014 1
2015 3
2016 4
2017 4
2018 4
2019 4
2020 4
2021 11
2022 5
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
2023 GEIS Guidelines for gastrointestinal stromal tumors.
Serrano C, Martín-Broto J, Asencio-Pascual JM, López-Guerrero JA, Rubió-Casadevall J, Bagué S, García-Del-Muro X, Fernández-Hernández JÁ, Herrero L, López-Pousa A, Poveda A, Martínez-Marín V. Serrano C, et al. Among authors: rubio casadevall j. Ther Adv Med Oncol. 2023 Aug 24;15:17588359231192388. doi: 10.1177/17588359231192388. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37655207 Free PMC article. Review.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
SEOM-TTCC clinical guideline in nasopharynx cancer (2021).
Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B, Iglesias Rey L, Rubió-Casadevall J, Arrazubi V, Mesía R. Rueda Domínguez A, et al. Among authors: rubio casadevall j. Clin Transl Oncol. 2022 Apr;24(4):670-680. doi: 10.1007/s12094-022-02814-x. Epub 2022 Mar 18. Clin Transl Oncol. 2022. PMID: 35303267 Free PMC article.
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure.
Botta L, Matsuda T, Charvat H, Chiang CJ, Lee WC, van Gestel AJ, Martin F, Geleijnse G, Cellamare M, Bonfarnuzzo S, Marcos-Gragera R, Guevara M, Mousavi M, Craig S, Rodrigues J, Rubió-Casadevall J, Licitra L, Cavalieri S, Resteghini C, Gatta G, Trama A; RARECAREnet working group. Botta L, et al. Among authors: rubio casadevall j. Front Oncol. 2023 Sep 13;13:1219111. doi: 10.3389/fonc.2023.1219111. eCollection 2023. Front Oncol. 2023. PMID: 37781187 Free PMC article.
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.
Rubió-Casadevall J, Cirauqui Cirauqui B, Martinez Trufero J, Plana Serrahima M, García Castaño A, Carral Maseda A, Iglesias Docampo L, Pérez Segura P, Ceballos Lenza I, Gutiérrez Calderón V, Fuster Salvà J, Pena Álvarez C, Hernandez I, Del Barco Morillo E, Chaves Conde M, Martínez Galán J, Durán Sánchez M, Quiroga V, Ortega E, Mesia R. Rubió-Casadevall J, et al. Front Oncol. 2023 Aug 1;13:1226939. doi: 10.3389/fonc.2023.1226939. eCollection 2023. Front Oncol. 2023. PMID: 37601652 Free PMC article.
Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.
Pilco Teran M, Merino Ribas A, Martin Alemany N, Barros Freiria X, Rubio Casadevall J, Pérez Bueno F, García Méndez I, Castillo Devia M, Noboa Paez C, Torguet Escuder P, Calabia Martínez J. Pilco Teran M, et al. Among authors: rubio casadevall j. Invest New Drugs. 2021 Feb;39(1):237-239. doi: 10.1007/s10637-020-00973-8. Epub 2020 Jul 9. Invest New Drugs. 2021. PMID: 32648118
E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
García-Valverde A, Rosell J, Sayols S, Gómez-Peregrina D, Pilco-Janeta DF, Olivares-Rivas I, de Álava E, Maurel J, Rubió-Casadevall J, Esteve A, Gut M, Valverde C, Barretina J, Carles J, Demetri GD, Fletcher JA, Arribas J, Serrano C. García-Valverde A, et al. Among authors: rubio casadevall j. Oncogene. 2021 Dec;40(48):6614-6626. doi: 10.1038/s41388-021-02049-0. Epub 2021 Oct 7. Oncogene. 2021. PMID: 34621020
41 results